Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2

NCT04110314
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal Reminders for Influenza Vaccination: Gain-framed, Portal Reminders for Influenza Vaccination: Loss-framed, Pre-commitment prompt
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Months and older
Enrollment
430,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Inactivated Influenza Via Jet Injection

NCT02290691
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza Vaccine
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
985 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influenza and Text Messaging in Pregnancy

NCT01248520
View directory record Official record
Conditions
Pregnancy
Interventions
influenza and general health information, general health information
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study

NCT05732610
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza B
Interventions
MGC Health COVID-19 & Flu A+B Home Multi Test, MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)
Diagnostic Test
Lead sponsor
Medical Group Care, LLC
Industry
Eligibility
2 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 15, 2026, 11:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

NCT01945424
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
5
States / cities
San Diego, California • Albany, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00516035
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 15, 2026, 11:39 AM EDT
Not listed No phase listed Observational

Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)

NCT03010410
View directory record Official record
Conditions
Sepsis, Influenza
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 15, 2026, 11:39 AM EDT
Completed No phase listed Observational

Influenza in People With Normal and Weakened Immune Systems

NCT00533182
View directory record Official record
Conditions
Viral Infections, Respiratory Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

NCT01091246
View directory record Official record
Conditions
Healthy or Stable Chronic Illness
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
2,312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Health Management Training to Enhance Influenza Vaccine Immunogenicity

NCT01256515
View directory record Official record
Conditions
No Conditions
Interventions
Health Education, Health Education Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

NCT01709019
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983
View directory record Official record
Conditions
Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions
MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
22 Months to 60 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
21
States / cities
Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively

NCT04109222
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 83 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 15, 2026, 11:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study

NCT01090557
View directory record Official record
Conditions
RSV Infection, Bronchiolitis
Interventions
Collection of exhaled breath
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
1 Day to 4 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2010 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)

NCT05535777
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
246,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 15, 2026, 11:39 AM EDT
Completed No phase listed Observational Results available

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

NCT01769430
View directory record Official record
Conditions
Influenza Virus Infection Transmission in Humans
Interventions
Observational Study of influenza aerosol shedding -- No Intervention
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
10 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 2 Interventional

Alternative Oseltamivir Dosing Strategies

NCT00334529
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® 2009-2010 Formula, FluMist® 2009-2010 Formula
Biological
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 15, 2026, 11:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

NCT00333398
View directory record Official record
Conditions
Influenza
Interventions
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
10
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 15, 2026, 11:39 AM EDT
Recruiting Phase 1 Interventional

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576
View directory record Official record
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 11:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

NCT00113880
View directory record Official record
Conditions
Healthy
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 49 Years
Enrollment
63,061 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
77
States / cities
Alameda, California • Antioch, California • Clovis, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 15, 2026, 11:39 AM EDT